{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:42:24Z","timestamp":1787240544920,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fundacion Alfonso Moreno Jaramillo","award":["2020-31631"],"award-info":[{"award-number":["2020-31631"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12032-022-01697-w","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T23:47:50Z","timestamp":1652744870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-379X","authenticated-orcid":false,"given":"Miguel","family":"Mendivil-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-2386","authenticated-orcid":false,"given":"Marlene","family":"Jimenez-Del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-0411","authenticated-orcid":false,"given":"Carlos","family":"Velez-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"issue":"3","key":"1697_CR1","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83\u20137.","journal-title":"Pathologica"},{"issue":"1","key":"1697_CR2","doi-asserted-by":"publisher","first-page":"e5426","DOI":"10.1590\/1414-431X20165426","volume":"50","author":"S Besbes","year":"2017","unstructured":"Besbes S, Hamadou WS, Boulland ML, Youssef YB, Achour B, Regaieg H, Khelif A, Fest T, Soua Z. Minimal residual disease detection in tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements. Braz J Med Biol Res. 2017;50(1):e5426. https:\/\/doi.org\/10.1590\/1414-431X20165426.","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"1697_CR3","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/s1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20(3):e142\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(19)30031-2.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524\u201339. https:\/\/doi.org\/10.3324\/haematol.2020.247031.","journal-title":"Haematologica"},{"issue":"1","key":"1697_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3324\/haematol.2015.131680","volume":"101","author":"T Oskarsson","year":"2016","unstructured":"Oskarsson T, S\u00f6derh\u00e4ll S, Arvidson J, Forestier E, Montgomery S, Bottai M, Lausen B, Carlsen N, Hellebostad M, L\u00e4hteenm\u00e4ki P, Saarinen-Pihkala UM, J\u00f3nsson \u00d3, Heyman M, group NSoPHaONArw. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016;101(1):68\u201376. https:\/\/doi.org\/10.3324\/haematol.2015.131680.","journal-title":"Haematologica"},{"issue":"16","key":"1697_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/blood.2019004043","volume":"136","author":"SP Hunger","year":"2020","unstructured":"Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136(16):1803\u201312. https:\/\/doi.org\/10.1182\/blood.2019004043.","journal-title":"Blood"},{"key":"1697_CR7","doi-asserted-by":"publisher","first-page":"e923271","DOI":"10.12659\/MSM.923271","volume":"26","author":"R Zhang","year":"2020","unstructured":"Zhang R, Zhu H, Yuan Y, Zhao J, Yang X, Tian Z. Risk factors for relapse of childhood B cell acute lymphoblastic leukemia. Med Sci Monit. 2020;26:e923271. https:\/\/doi.org\/10.12659\/MSM.923271.","journal-title":"Med Sci Monit"},{"key":"1697_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004;22:247\u2013306. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104753.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"1697_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792.","journal-title":"Am J Hematol"},{"issue":"2","key":"1697_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1517\/14656566.2011.533169","volume":"12","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Jung-Munkwitz S, Saussele S. Treatment of chronic myeloid leukemia when imatinib fails. Expert Opin Pharmacother. 2011;12(2):269\u201383. https:\/\/doi.org\/10.1517\/14656566.2011.533169.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1697_CR11","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.21873\/anticanres.14215","volume":"40","author":"M Massimino","year":"2020","unstructured":"Massimino M, Stella S, Tirr\u00f2 E, Pennisi MS, Vitale SR, Puma A, Romano C, Di Gregorio S, Tomarchio C, Di Raimondo F, Manzella L. ABL1-directed inhibitors for CML: efficacy, resistance and future perspectives. Anticancer Res. 2020;40(5):2457\u201365. https:\/\/doi.org\/10.21873\/anticanres.14215.","journal-title":"Anticancer Res"},{"key":"1697_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194820","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las RJ, Trougakos IP, Sarmento Ribeiro AB. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194820.","journal-title":"Cancers (Basel)"},{"key":"1697_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-017-1375-1","author":"R Rathore","year":"2017","unstructured":"Rathore R, McCallum JE, Varghese E, Florea AM, Busselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis. 2017. https:\/\/doi.org\/10.1007\/s10495-017-1375-1.","journal-title":"Apoptosis"},{"issue":"3","key":"1697_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D\u2019Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jaattela M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, Lopez-Otin C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Munoz-Pinedo C, Nagata S, Nunez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486\u2013541. https:\/\/doi.org\/10.1038\/s41418-017-0012-4.","journal-title":"Cell Death Differ"},{"issue":"11\u201312","key":"1697_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00018-016-2209-y","volume":"73","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi L, Bravo-San Pedro JM, Kepp O, Kroemer G. Regulated cell death and adaptive stress responses. Cell Mol Life Sci. 2016;73(11\u201312):2405\u201310. https:\/\/doi.org\/10.1007\/s00018-016-2209-y.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1697_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/2211068216681979","volume":"22","author":"DK Lee","year":"2017","unstructured":"Lee DK, Chang VY, Kee T, Ho CM, Ho D. Optimizing combination therapy for acute lymphoblastic leukemia using a phenotypic personalized medicine digital health platform: retrospective optimization individualizes patient regimens to maximize efficacy and safety. SLAS Technol. 2017;22(3):276\u201388. https:\/\/doi.org\/10.1177\/2211068216681979.","journal-title":"SLAS Technol"},{"key":"1697_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2019.00665","volume":"9","author":"PE Westerweel","year":"2019","unstructured":"Westerweel PE, Te Boekhorst PAW, Levin MD, Cornelissen JJ. New approaches and treatment combinations for the management of chronic myeloid leukemia. Front Oncol. 2019;9:665. https:\/\/doi.org\/10.3389\/fonc.2019.00665.","journal-title":"Front Oncol"},{"key":"1697_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163556","author":"JL Stokke","year":"2021","unstructured":"Stokke JL, Bhojwani D. Antibody-drug conjugates for the treatment of acute pediatric leukemia. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10163556.","journal-title":"J Clin Med"},{"issue":"W1","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"W174","DOI":"10.1093\/nar\/gkab438","volume":"49","author":"S Zheng","year":"2021","unstructured":"Zheng S, Aldahdooh J, Shadbahr T, Wang Y, Aldahdooh D, Bao J, Wang W, Tang J. DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal. Nucleic Acids Res. 2021;49(W1):W174\u201384. https:\/\/doi.org\/10.1093\/nar\/gkab438.","journal-title":"Nucleic Acids Res"},{"key":"1697_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-cancerbio-041916-065808","volume":"1","author":"C Reczek","year":"2017","unstructured":"Reczek C, Chandel N. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 2017;1:79\u201398. https:\/\/doi.org\/10.1146\/annurev-cancerbio-041916-065808.","journal-title":"Annu Rev Cancer Biol"},{"key":"1697_CR21","doi-asserted-by":"publisher","first-page":"294303","DOI":"10.1155\/2015\/294303","volume":"2015","author":"J Liu","year":"2015","unstructured":"Liu J, Wang Z. Increased oxidative stress as a selective anticancer therapy. Oxid Med Cell Longev. 2015;2015:294303. https:\/\/doi.org\/10.1155\/2015\/294303.","journal-title":"Oxid Med Cell Longev"},{"issue":"11","key":"1697_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s10495-017-1424-9","volume":"22","author":"Z Zou","year":"2017","unstructured":"Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 2017;22(11):1321\u201335. https:\/\/doi.org\/10.1007\/s10495-017-1424-9.","journal-title":"Apoptosis"},{"key":"1697_CR23","doi-asserted-by":"publisher","first-page":"5381692","DOI":"10.1155\/2019\/5381692","volume":"2019","author":"SJ Kim","year":"2019","unstructured":"Kim SJ, Kim HS, Seo YR. Understanding of ROS-inducing strategy in anticancer therapy. Oxid Med Cell Longev. 2019;2019:5381692. https:\/\/doi.org\/10.1155\/2019\/5381692.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"1697_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192\u2013203. https:\/\/doi.org\/10.1038\/s12276-020-0384-2.","journal-title":"Exp Mol Med"},{"key":"1697_CR25","doi-asserted-by":"publisher","first-page":"313275","DOI":"10.1155\/2012\/313275","volume":"2012","author":"M Mendivil-Perez","year":"2012","unstructured":"Mendivil-Perez M, Velez-Pardo C, Jimenez-Del-Rio M. TPEN induces apoptosis independently of zinc chelator activity in a model of acute lymphoblastic leukemia and ex vivo acute leukemia cells through oxidative stress and mitochondria caspase-3- and AIF-dependent pathways. Oxid Med Cell Longev. 2012;2012:313275. https:\/\/doi.org\/10.1155\/2012\/313275.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1697_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10534-020-00262-0","volume":"34","author":"M Mendivil-Perez","year":"2021","unstructured":"Mendivil-Perez M, Velez-Pardo C, David-Yepes GE, Fox JE, Jimenez-Del-Rio M. TPEN exerts selective anti-leukemic efficacy in ex vivo drug-resistant childhood acute leukemia. Biometals. 2021;34(1):49\u201366. https:\/\/doi.org\/10.1007\/s10534-020-00262-0.","journal-title":"Biometals"},{"key":"1697_CR27","doi-asserted-by":"publisher","unstructured":"Mendivil-Perez M, Velez-Pardo C, Quiroz-Duque L, Restrepo-Rincon A, Valencia-Zuluaga N, Jimenez-Del-Rio M (2021) TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients. Preprints https:\/\/doi.org\/10.20944\/preprints202103.0611.v2","DOI":"10.20944\/preprints202103.0611.v2"},{"key":"1697_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-017-0015-0","author":"L Rojas-Valencia","year":"2017","unstructured":"Rojas-Valencia L, Velez-Pardo C, Jimenez-Del-Rio M. Metal chelator TPEN selectively induces apoptosis in K562 cells through reactive oxygen species signaling mechanism: implications for chronic myeloid leukemia. Biometals. 2017. https:\/\/doi.org\/10.1007\/s10534-017-0015-0.","journal-title":"Biometals"},{"key":"1697_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-4501-6_45-1","volume-title":"Handbook of oxidative stress in cancer: mechanistic aspects","author":"C Velez-Pardo","year":"2021","unstructured":"Velez-Pardo C, Jimenez-Del-Rio M. Helping leukemia cells to die with natural or chemical compounds through H2O2 signaling. In: Chakraborti S, Ray B, Roychoudhury S, editors. Handbook of oxidative stress in cancer: mechanistic aspects. Singapore: Springer; 2021. https:\/\/doi.org\/10.1007\/978-981-15-4501-6_45-1."},{"issue":"1\u20132","key":"1697_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijpharm.2017.01.020","volume":"519","author":"A Abu-Fayyad","year":"2017","unstructured":"Abu-Fayyad A, Nazzal S. Synthesis, characterization, and in-vitro antitumor activity of the polyethylene glycol (350 and 1000) succinate derivatives of the tocopherol and tocotrienol isomers of vitamin E. Int J Pharm. 2017;519(1\u20132):145\u201356. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.01.020.","journal-title":"Int J Pharm"},{"issue":"9","key":"1697_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10495-016-1266-x","volume":"21","author":"C Ruiz-Moreno","year":"2016","unstructured":"Ruiz-Moreno C, Jimenez-Del-Rio M, Sierra-Garcia L, Lopez-Osorio B, Velez-Pardo C. Vitamin E synthetic derivate-TPGS-selectively induces apoptosis in jurkat t cells via oxidative stress signaling pathways: implications for acute lymphoblastic leukemia. Apoptosis. 2016;21(9):1019\u201332. https:\/\/doi.org\/10.1007\/s10495-016-1266-x.","journal-title":"Apoptosis"},{"key":"1697_CR32","doi-asserted-by":"publisher","first-page":"5580288","DOI":"10.1155\/2021\/5580288","volume":"2021","author":"J Calvo-Alvarez","year":"2021","unstructured":"Calvo-Alvarez J, Jimenez-Del-Rio M, Velez-Pardo C. Vitamin E TPGS 1000 induces apoptosis in the K562 cell line: implications for chronic myeloid leukemia. Oxid Med Cell Longev. 2021;2021:5580288. https:\/\/doi.org\/10.1155\/2021\/5580288.","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"1697_CR33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1021\/acs.chemrestox.8b00138","volume":"31","author":"C Ruiz-Moreno","year":"2018","unstructured":"Ruiz-Moreno C, Velez-Pardo C, Jimenez-Del-Rio M. Vitamin E d-alpha-tocopheryl polyethylene glycol succinate (TPGS) provokes cell death in human neuroblastoma SK-N-SH cells via a pro-oxidant signaling mechanism. Chem Res Toxicol. 2018;31(9):945\u201353. https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00138.","journal-title":"Chem Res Toxicol"},{"key":"1697_CR34","doi-asserted-by":"publisher","first-page":"9.19.11","DOI":"10.1002\/0471141755.ph0919s72","volume":"72","author":"RJ Tallarida","year":"2016","unstructured":"Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Protoc Pharmacol. 2016;72:9.19.11-19.19.19. https:\/\/doi.org\/10.1002\/0471141755.ph0919s72.","journal-title":"Curr Protoc Pharmacol"},{"key":"1697_CR35","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3389\/fphar.2019.01222","volume":"10","author":"RY Huang","year":"2019","unstructured":"Huang RY, Pei L, Liu Q, Chen S, Dou H, Shu G, Yuan ZX, Lin J, Peng G, Zhang W, Fu H. Isobologram analysis: a comprehensive review of methodology and current research. Front Pharmacol. 2019;10:1222. https:\/\/doi.org\/10.3389\/fphar.2019.01222.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1697_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.bbrc.2004.03.110","volume":"317","author":"T Kinumi","year":"2004","unstructured":"Kinumi T, Kimata J, Taira T, Ariga H, Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2004;317(3):722\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2004.03.110.","journal-title":"Biochem Biophys Res Commun"},{"key":"1697_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-10-6583-5_1","volume":"1037","author":"H Ariga","year":"2017","unstructured":"Ariga H, Iguchi-Ariga SMM. Introduction\/overview. Adv Exp Med Biol. 2017;1037:1\u20134. https:\/\/doi.org\/10.1007\/978-981-10-6583-5_1.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"1697_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11914-017-0378-8","volume":"15","author":"RW Johnson","year":"2017","unstructured":"Johnson RW, Sowder ME, Giaccia AJ. Hypoxia and bone metastatic disease. Curr Osteoporos Rep. 2017;15(4):231\u20138. https:\/\/doi.org\/10.1007\/s11914-017-0378-8.","journal-title":"Curr Osteoporos Rep"},{"issue":"14","key":"1697_CR39","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2017-12-784132","volume":"131","author":"D Duarte","year":"2018","unstructured":"Duarte D, Hawkins ED, Lo Celso C. The interplay of leukemia cells and the bone marrow microenvironment. Blood. 2018;131(14):1507\u201311. https:\/\/doi.org\/10.1182\/blood-2017-12-784132.","journal-title":"Blood"},{"issue":"11","key":"1697_CR40","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1038\/s41375-021-01248-8","volume":"35","author":"JW B\u04e7hm","year":"2021","unstructured":"B\u04e7hm JW, Sia KCS, Jones C, Evans K, Mariana A, Pang I, Failes T, Zhong L, Mayoh C, Landman R, Collins R, Erickson SW, Arndt G, Raftery MJ, Wilkins MR, Norris MD, Haber M, Marshall GM, Lock RB. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia. Leukemia. 2021;35(11):3101\u201312. https:\/\/doi.org\/10.1038\/s41375-021-01248-8.","journal-title":"Leukemia"},{"issue":"22","key":"1697_CR41","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood.2018882233","volume":"133","author":"N Hijiya","year":"2019","unstructured":"Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374\u201384. https:\/\/doi.org\/10.1182\/blood.2018882233.","journal-title":"Blood"},{"key":"1697_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040669","author":"Y Gilad","year":"2021","unstructured":"Gilad Y, Gellerman G, Lonard DM, O\u2019Malley BW. Drug combination in cancer treatment-from cocktails to conjugated combinations. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040669.","journal-title":"Cancers (Basel)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01697-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01697-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01697-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T09:39:28Z","timestamp":1656409168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01697-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01697-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were following the ethical standards of the Ethics Committee for Research Act # 04-2018 from Children\u2019s Hospital Universitario San Vicente Fundaci\u00f3n and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from pediatric ex vivo B-ALL and control cells collected in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Consent for publication was obtained from pediatric ex vivo B-ALL and control cells collected in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"109"}}